vs
Side-by-side financial comparison of Citius Pharmaceuticals, Inc. (CTXR) and TECOGEN INC. (TGEN). Click either name above to swap in a different company.
TECOGEN INC. is the larger business by last-quarter revenue ($5.3M vs $3.9M, roughly 1.3× Citius Pharmaceuticals, Inc.). TECOGEN INC. runs the higher net margin — -75.1% vs -238.2%, a 163.1% gap on every dollar of revenue.
Citius Pharmaceuticals, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing innovative prescription therapies addressing unmet medical needs across critical care, oncology, anti-infective treatment, and supportive care segments, primarily serving the U.S. healthcare market.
CTXR vs TGEN — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $3.9M | $5.3M |
| Net Profit | $-9.4M | $-4.0M |
| Gross Margin | 80.0% | 36.8% |
| Operating Margin | -228.7% | -77.8% |
| Net Margin | -238.2% | -75.1% |
| Revenue YoY | — | -12.5% |
| Net Profit YoY | 8.6% | -236.7% |
| EPS (diluted) | $-0.38 | $-0.14 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $3.9M | $5.3M | ||
| Q3 25 | — | $7.2M | ||
| Q2 25 | — | $7.3M | ||
| Q1 25 | — | $7.3M | ||
| Q4 24 | — | $6.1M | ||
| Q3 24 | — | $5.6M | ||
| Q2 24 | — | $4.7M | ||
| Q1 24 | — | $6.2M |
| Q4 25 | $-9.4M | $-4.0M | ||
| Q3 25 | — | $-2.1M | ||
| Q2 25 | — | $-1.5M | ||
| Q1 25 | — | $-659.9K | ||
| Q4 24 | — | $-1.2M | ||
| Q3 24 | — | $-930.4K | ||
| Q2 24 | — | $-1.5M | ||
| Q1 24 | — | $-1.1M |
| Q4 25 | 80.0% | 36.8% | ||
| Q3 25 | — | 30.4% | ||
| Q2 25 | — | 33.8% | ||
| Q1 25 | — | 44.3% | ||
| Q4 24 | — | 45.0% | ||
| Q3 24 | — | 44.1% | ||
| Q2 24 | — | 44.0% | ||
| Q1 24 | — | 41.6% |
| Q4 25 | -228.7% | -77.8% | ||
| Q3 25 | — | -29.2% | ||
| Q2 25 | — | -19.4% | ||
| Q1 25 | — | -8.2% | ||
| Q4 24 | — | -18.7% | ||
| Q3 24 | — | -15.5% | ||
| Q2 24 | — | -31.2% | ||
| Q1 24 | — | -17.0% |
| Q4 25 | -238.2% | -75.1% | ||
| Q3 25 | — | -29.7% | ||
| Q2 25 | — | -20.1% | ||
| Q1 25 | — | -9.1% | ||
| Q4 24 | — | -19.5% | ||
| Q3 24 | — | -16.5% | ||
| Q2 24 | — | -32.5% | ||
| Q1 24 | — | -17.9% |
| Q4 25 | $-0.38 | $-0.14 | ||
| Q3 25 | — | $-0.07 | ||
| Q2 25 | — | $-0.06 | ||
| Q1 25 | — | $-0.03 | ||
| Q4 24 | — | $-0.05 | ||
| Q3 24 | — | $-0.04 | ||
| Q2 24 | — | $-0.06 | ||
| Q1 24 | — | $-0.04 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $7.7M | $12.4M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $80.0M | $21.6M |
| Total Assets | $140.4M | $37.0M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $7.7M | $12.4M | ||
| Q3 25 | — | $15.3M | ||
| Q2 25 | — | $1.6M | ||
| Q1 25 | — | $4.1M | ||
| Q4 24 | — | $5.4M | ||
| Q3 24 | — | $1.3M | ||
| Q2 24 | — | $841.9K | ||
| Q1 24 | — | $1.5M |
| Q4 25 | $80.0M | $21.6M | ||
| Q3 25 | — | $25.5M | ||
| Q2 25 | — | $9.1M | ||
| Q1 25 | — | $9.6M | ||
| Q4 24 | — | $10.2M | ||
| Q3 24 | — | $11.3M | ||
| Q2 24 | — | $12.2M | ||
| Q1 24 | — | $13.7M |
| Q4 25 | $140.4M | $37.0M | ||
| Q3 25 | — | $41.5M | ||
| Q2 25 | — | $28.4M | ||
| Q1 25 | — | $29.7M | ||
| Q4 24 | — | $31.1M | ||
| Q3 24 | — | $27.5M | ||
| Q2 24 | — | $27.2M | ||
| Q1 24 | — | $28.5M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-13.0M | $-2.6M |
| Free Cash FlowOCF − Capex | — | $-2.6M |
| FCF MarginFCF / Revenue | — | -49.3% |
| Capex IntensityCapex / Revenue | — | 0.9% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-10.3M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-13.0M | $-2.6M | ||
| Q3 25 | — | $-3.6M | ||
| Q2 25 | — | $-2.6M | ||
| Q1 25 | — | $-1.2M | ||
| Q4 24 | — | $4.2M | ||
| Q3 24 | — | $-207.3K | ||
| Q2 24 | — | $-157.9K | ||
| Q1 24 | — | $248.2K |
| Q4 25 | — | $-2.6M | ||
| Q3 25 | — | $-3.6M | ||
| Q2 25 | — | $-2.7M | ||
| Q1 25 | — | $-1.3M | ||
| Q4 24 | — | $4.0M | ||
| Q3 24 | — | $-489.6K | ||
| Q2 24 | — | $-609.6K | ||
| Q1 24 | — | $143.3K |
| Q4 25 | — | -49.3% | ||
| Q3 25 | — | -50.6% | ||
| Q2 25 | — | -37.7% | ||
| Q1 25 | — | -17.9% | ||
| Q4 24 | — | 66.6% | ||
| Q3 24 | — | -8.7% | ||
| Q2 24 | — | -12.9% | ||
| Q1 24 | — | 2.3% |
| Q4 25 | — | 0.9% | ||
| Q3 25 | — | 1.0% | ||
| Q2 25 | — | 2.0% | ||
| Q1 25 | — | 1.8% | ||
| Q4 24 | — | 2.1% | ||
| Q3 24 | — | 5.0% | ||
| Q2 24 | — | 9.6% | ||
| Q1 24 | — | 1.7% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CTXR
Segment breakdown not available.
TGEN
| Installation Services | $4.5M | 84% |
| Products Segment | $460.5K | 9% |
| Other | $394.7K | 7% |
